[ANMCO Position paper: Vericiguat use in heart failure: from evidence to place in therapy]. / Position paper ANMCO: Impiego di vericiguat nello scompenso cardiaco: dalle evidenze al posizionamento terapeutico.
G Ital Cardiol (Rome)
; 24(4): 323-331, 2023 Apr.
Article
em It
| MEDLINE
| ID: mdl-36971177
ABSTRACT
In the growing therapeutic armamentarium for heart failure management, vericiguat represents an innovative therapeutic option. The biological target of this drug is different from that of other drugs for heart failure. Indeed, vericiguat does not inhibit neurohormonal systems overactivated in heart failure or sodium-glucose cotransporter 2 but stimulates the biological pathway of nitric oxide and cyclic guanosine monophosphate, which is impaired in patients with heart failure. Vericiguat has recently been approved by international and national regulatory authorities for the treatment of patients with heart failure and reduced ejection fraction who are symptomatic despite optimal medical therapy and have worsening heart failure. This ANMCO position paper summarizes key aspects of vericiguat mechanism of action and provides a review of available clinical evidence. Furthermore, this document reports use indications based on international guideline recommendations and local regulatory authority approval at the time of writing.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Disfunção Ventricular Esquerda
/
Insuficiência Cardíaca
/
Compostos Heterocíclicos com 2 Anéis
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
It
Revista:
G Ital Cardiol (Rome)
Assunto da revista:
CARDIOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article